The Ebola epidemic is continuing to spread, particularly in West Africa. According to the latest report by the World Health Organisation (WHO) dated 17 October, 9,216 cases of Ebola have been recorded and 4,555 people have died of the virus.
With the current situation of the Ebola epidemic, it quickly became necessary for French research to be mobilised rapidly.
With extensive past experience and recognised for coordinating research during the H1N1 epidemic in 2009 and more recently in response to the emergence of the Chikungunya virus in the Caribbean in 2013, the Aviesan Institute of Microbiology and Infectious Disease benefitted from the expertise of the REACTing network to launch the Ebola research programme.
This network relies on existing teams, research centres and platforms in France and southern countries.
The implementation of these projects is coordinated mainly by teams from Inserm, CEA, the Pasteur Institute, IRD, Universities, not forgetting a close partnership with teams in Guinea, Ivory Coast and Senegal. The network of ANRS sites and researchers in West Africa have also been mobilised.
The French Plan for Genomic Medicine 2025 was presented to Prime Minister Manuel Valls by Yves Lévy, President of the National Alliance for Life Sciences and Health (Aviesan) and CEO of Inserm, on 22 June 2016. ...
Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows ...
Videos of the laboratory P4 available on demand to email@example.com